PLK1 and cancer: Arbutus Biopharma Corporation developed TKM-080301, a LNP formulation of a PLK1 siRNA targeting human PLK1.602 TKM-080301 demonstrated strong antiproliferative effects and gene-specific silencing in cancer cell lines, showing antitumor activity in PDX models of tumors implanted intrahepatically or subcutaneously.603 Its toxicity was mainly limited to the liver and spleen in HCC patients, reflecting the distribution of the LNPs.603 An open‐label, multicenter, dose escalation study revealed that the antitumor effect of TKM 080301 as a single agent was limited (NCT02191878).